Skip to Content
Merck
CN
All Photos(1)

Key Documents

S8072

Sigma-Aldrich

Sertindole

≥97.5% (HPLC)

Synonym(s):

1-[2-[4-[5-Chloro-1-(4-fluorophenyl)-1h-indol-3-yl]-1-piperidinyl]ethyl]-2-imidazolidinone

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C24H26ClFN4O
CAS Number:
Molecular Weight:
440.94
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Assay

≥97.5% (HPLC)

form

solid

color

off-white

solubility

DMSO: >10 mg/mL
H2O: <2 mg/mL

originator

Abbott

storage temp.

2-8°C

SMILES string

Fc1ccc(cc1)-n2cc(C3CCN(CC3)CCN4CCNC4=O)c5cc(Cl)ccc25

InChI

1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)

InChI key

GZKLJWGUPQBVJQ-UHFFFAOYSA-N

Gene Information

Application

Sertindole was used to study the role of 5-HT2C receptor in antipsychotic-induced body weight gain in rats.3

Biochem/physiol Actions

Sertindole is a 5-HT2 serotonin and D2 dopamine receptor antagonist and antipsychotic.
Sertindole readily passes the blood-brain barrier and is metabolized into compounds that show greater affinity for 5-HT2 receptors and less for D2 receptors. It is an effective treatment agent for schizophrenia as it improves cognitive impairment.1 Sertindole also acts as antagonist to human cardiac potassium channel, HERG and produces prolonged QT interval.2

Features and Benefits

This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Katja Komossa et al.
The Cochrane database of systematic reviews, (2)(2), CD006752-CD006752 (2009-04-17)
In many countries of the industrialised world second generation (atypical) antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether and, if so, how much the effects of the various second generation antipsychotics
Lars Boukharta et al.
Biochemistry, 50(27), 6146-6156 (2011-06-11)
The hERG potassium channel is of major pharmaceutical importance, and its blockade by various compounds, potentially causing serious cardiac side effects, is a major problem in drug development. Despite the large amounts of existing biochemical data on blockade of hERG
Eva Lindström et al.
Expert opinion on pharmacotherapy, 7(13), 1825-1834 (2006-08-24)
Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a
Eva Lindström et al.
Nordic journal of psychiatry, 65(6), 403-413 (2011-07-21)
Atypical antipsychotics have similar clinical efficacy in the treatment of schizophrenia; variability in their tolerability represents the discerning factor in treatment choices. Sertindole has a relatively good tolerability profile that favours long-term patient adherence and, therefore, is associated with lower
R E Nielsen et al.
Acta psychiatrica Scandinavica, 126(1), 31-39 (2012-02-24)
To assess the cognitive effects of sertindole augmentation in clozapine-treated patients diagnosed with schizophrenia. Cognition is secondary outcome of the trial. A 12-week, double-blinded, randomized, placebo-controlled, augmentation study of patients treated with clozapine. Participants were randomized 1:1 to receive 16

Articles

We offer many products related to dopamine receptors for your research needs.

We offer many products related to serotonin receptors for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service